CCAPCrescent Capital BDC, Inc.
Is the price fair?
At the top of its own P/E range. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Expensive vs its own history: P/E 8.8 vs a 6.1 median over 16 quarters (+43% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CCAP's price assumes
Crescent Capital BDC, Inc. has no trailing P/E on file, so the price is measured against sales instead: 2.57× revenue.
Price / sales · no trailing P/E on file: measured against sales instead
- Price / book
- 0.61
Price / book · as of 2026-Q2
- EV / sales
- 8.37
EV / sales
Details›
- Price / bookas of 2026-Q2
- 0.61
- EV / salesas of 2026-Q2
- 8.37
- Market capitalisation36.8 million shares, counted Aug 10, 2026
- $319M
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $6.96 |
| Its own P/E history, median | $7.64 |
| Its own P/E history, upper quartile | $8.42 |
| 52-week range | $8.52 – $14.31 |
| Today | $8.66 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Asset Management
The closest names by size in the same industry